v3.26.3
SEGMENT REPORTING (Details) - USD ($)
 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Line Items]      
Number Of Reportable Segments Disclosed By Definition Flag true true  
Revenue $ 1,386,608 $ 1,129,238  
Cost of revenue (829,124) (740,172)  
Gross profit 557,484 389,066  
Operating expenses 2,719,661 1,998,808  
Operating profit (loss) (2,162,177) (1,609,742)  
Other income (expenses), net (28) 7,649  
Profit (loss) before income tax (2,162,205) (1,602,093)  
Identifiable long-lived assets 159,926 667,025  
Total assets 8,911,138 5,791,578 $ 2,817,180
Corporate and Unallocated      
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Line Items]      
Operating expenses 971,674 785,857  
Operating profit (loss) (971,674) (785,857)  
Other income (expenses), net   17,835  
Profit (loss) before income tax (971,674) (768,022)  
Identifiable long-lived assets 149,180 648,831  
Total assets 8,215,322 1,588,821  
Exosome Products | Operating segments      
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Line Items]      
Revenue 1,386,608 1,129,238  
Cost of revenue (829,124) (740,172)  
Gross profit 557,484 389,066  
Operating expenses 367,989 345,929  
Operating profit (loss) 189,495 43,137  
Other income (expenses), net (28) (10,186)  
Profit (loss) before income tax 189,467 32,951  
Identifiable long-lived assets 10,746 18,194  
Total assets 695,816 4,202,757  
CD-19 Armed-T Products | Operating segments      
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Line Items]      
Operating expenses 128,536 357,468  
Operating profit (loss) (128,536) (357,468)  
Profit (loss) before income tax (128,536) (357,468)  
GDT cell therapy Products | Operating segments      
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Line Items]      
Operating expenses 1,251,462 509,554  
Operating profit (loss) (1,251,462) (509,554)  
Profit (loss) before income tax $ (1,251,462) $ (509,554)